Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 1;7(1):30-40.
doi: 10.4049/immunohorizons.2200095.

KIR Allelic Variation and the Remission of Atopic Dermatitis Over Time

Affiliations

KIR Allelic Variation and the Remission of Atopic Dermatitis Over Time

David J Margolis et al. Immunohorizons. .

Abstract

Atopic dermatitis (AD) is a common chronic skin disease. Although generally thought to be a disease of T-cell dysregulation, recent studies have suggested that immune dysregulation of NK cells is also important. Killer cell Ig-like receptors (KIRs) are involved with NK cell regulation. The Pediatric Eczema Elective Registry is a U.S. nationwide longitudinal cohort with up to 10 y of follow-up in which 655 children had DNA available for full allelic KIR sequencing. Every 6 mo, AD activity was reported by Pediatric Eczema Elective Registry children. Using generalized estimating equations, we evaluated the association of KIR allelic variation in concert with known HLA binding ligands and whether the child reported AD in "remission" (no skin lesions and not using AD medication). KIR2DS4*001:01 (odds ratio 0.53, 95% CI [0.32, 0.88]) and KIR2DL4*001:02 (0.54, [0.33, 0.89]) in the presence of C*04:01 had the largest effect on decreasing the likelihood of AD remission. The haplotype KIR 2DL4*001:02 ∼ 2DS4*001:01 ∼ 3DL2*002:01 (0.77, [0.60, 0.99]) was also associated with a decreased likelihood of AD remission. Our findings add to the general body of evidence of a growing literature on the importance of NK cells with respect to the immunopathogenesis and natural history of AD.

PubMed Disclaimer

Conflict of interest statement

D.J.M. is or recently has been a consultant for Pfizer, Leo, and Sanofi with respect to studies of atopic dermatitis and served on an advisory board for the National Eczema Association. The other authors do not report potential conflicts of interest with respect to the materials in this article.

Figures

FIGURE 1. Presence or absence of KIR2DL4*001:02 and HLA-C*04:01 status and the percentage of children in remission using surveys as described in Materials and Methods over time.
FIGURE 1.
Presence or absence of KIR2DL4*001:02 and HLA-C*04:01 status and the percentage of children in remission using surveys as described in Materials and Methods over time.

References

    1. Abramovits W. 2005. Atopic dermatitis. J. Am. Acad. Dermatol. 53(1 Suppl):S86–S93. - PubMed
    1. Eichenfield L. F., Tom W. L., Chamlin S. L., Feldman S. R., Hanifin J. M., Simpson E. L., Berger T. G., Bergman J. N., Cohen D. E., Cooper K. D., et al. 2014. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J. Am. Acad. Dermatol. 70: 338–351. - PMC - PubMed
    1. Del Pozo D. V., Zhu Y., Mitra N., Hoffstad O. J., Margolis D. J.. 2022. The risk of atopic comorbidities and atopic march progression among Black and White children with mild-to-moderate atopic dermatitis: a cross-sectional study. J. Am. Acad. Dermatol. 87: 1145–1147. - PubMed
    1. Margolis J. S., Abuabara K., Bilker W., Hoffstad O., Margolis D. J.. 2014. Persistence of mild to moderate atopic dermatitis. JAMA Dermatol. 150: 593–600. - PMC - PubMed
    1. Kapoor R., Menon C., Hoffstad O., Bilker W., Leclerc P., Margolis D. J.. 2008. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J. Am. Acad. Dermatol. 58: 68–73. - PubMed

Publication types